Achiko AG announced that the Ministry of Health of the Republic of Indonesia has granted full product registration approval for its optimised, second-generation Covid-19 rapid test AptameXTM, alongside its sister digital passporting service, Teman SehatTM ("Health Buddy"). The Company has completed initial production of its first-generation product and is currently commissioning the production capacity for its second-generation product with production to commence later this month. There is a temporary production constraint to secure custom moulding for plastics to resolve and to finalise quality control of the initial first-generation production. The Company expects the issues to be resolved shortly. The company is making progress with its CE Mark, and expects to have a declaration of conformity in First Quarter 2022. The two material items outstanding are the appointment of an original equipment manufacturer (OEM) partner and the completion of the clinical investigation report. The former is being secured shortly. For the clinical investigation report, a site to conduct the clinical investigation outside of Indonesia is in the process of being secured. The Company has formally commenced discussions to start commercialisation of its test kits in other parts of Asia, the Middle East and northern Africa (MENA), and eastern Europe. Samples of AptameX second-generation test kits are being shipped to these locations for product sampling and demonstrations to be held this month.